Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells

BACKGROUND: Multidrug resistance (MDR) is a major obstacle in breast cancer treatment. The predominant mechanism underlying MDR is an increase in the activity of adenosine triphosphate (ATP)-dependent drug efflux transporters. Sulbactam, a β-lactamase inhibitor, is generally combined with β-lactam a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Shao-hsuan, Su, Shey-chiang, Liou, Bo-huang, Lin, Cheng-hao, Lee, Kuan-rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123926/
https://www.ncbi.nlm.nih.gov/pubmed/30202239
http://dx.doi.org/10.1186/s12935-018-0625-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123926/
https://www.ncbi.nlm.nih.gov/pubmed/30202239
http://dx.doi.org/10.1186/s12935-018-0625-9

Ejemplares similares